151 related articles for article (PubMed ID: 36471872)
1. mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern.
Wang G; Shi J; Verma AK; Guan X; Perlman S; Du L
iScience; 2022 Dec; 25(12):105690. PubMed ID: 36471872
[TBL] [Abstract][Full Text] [Related]
2. Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern.
Shi J; Wang G; Zheng J; Verma AK; Guan X; Malisheni MM; Geng Q; Li F; Perlman S; Du L
NPJ Vaccines; 2022 Dec; 7(1):169. PubMed ID: 36535987
[TBL] [Abstract][Full Text] [Related]
3. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood.
Govindaraj S; Cheedarla N; Cheedarla S; Irby LS; Neish AS; Roback JD; Smith AK; Velu V
Front Immunol; 2023; 14():1211558. PubMed ID: 37465682
[TBL] [Abstract][Full Text] [Related]
5. Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge.
Guan X; Verma AK; Wang G; Shi J; Perlman S; Du L
iScience; 2023 Oct; 26(10):108033. PubMed ID: 37822493
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
Front Immunol; 2022; 13():981693. PubMed ID: 36225911
[TBL] [Abstract][Full Text] [Related]
7. Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.
Takheaw N; Liwsrisakun C; Chaiwong W; Laopajon W; Pata S; Inchai J; Duangjit P; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Kasinrerk W
Diagnostics (Basel); 2022 May; 12(6):. PubMed ID: 35741126
[TBL] [Abstract][Full Text] [Related]
8. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
[TBL] [Abstract][Full Text] [Related]
9. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant.
Schubert M; Bertoglio F; Steinke S; Heine PA; Ynga-Durand MA; Maass H; Sammartino JC; Cassaniti I; Zuo F; Du L; Korn J; Milošević M; Wenzel EV; Krstanović F; Polten S; Pribanić-Matešić M; Brizić I; Baldanti F; Hammarström L; Dübel S; Šustić A; Marcotte H; Strengert M; Protić A; Piralla A; Pan-Hammarström Q; Čičin-Šain L; Hust M
BMC Med; 2022 Mar; 20(1):102. PubMed ID: 35236358
[TBL] [Abstract][Full Text] [Related]
10. A Novel Targeted RIG-I Receptor 5'Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine.
Bai Y; An C; Zhang X; Li K; Cheng F; Cui B; Song Z; Liu D; Zhang J; He Q; Liu J; Mao Q; Liang Z
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243185
[TBL] [Abstract][Full Text] [Related]
11. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
[TBL] [Abstract][Full Text] [Related]
12. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates.
Malewana RD; Stalls V; May A; Lu X; Martinez DR; Schäfer A; Li D; Barr M; Sutherland LL; Lee E; Parks R; Beck WE; Newman A; Bock KW; Minai M; Nagata BM; DeMarco CT; Denny TN; Oguin TH; Rountree W; Wang Y; Mansouri K; Edwards RJ; Sempowski GD; Eaton A; Muramatsu H; Henderson R; Tam Y; Barbosa C; Tang J; Cain DW; Santra S; Moore IN; Andersen H; Lewis MG; Golding H; Seder R; Khurana S; Montefiori DC; Pardi N; Weissman D; Baric RS; Acharya P; Haynes BF; Saunders KO
bioRxiv; 2023 Dec; ():. PubMed ID: 38187726
[TBL] [Abstract][Full Text] [Related]
14. Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster.
Peng P; Feng C; Hu J; He C; Deng H; Fan Q; Xiang J; Tang G; Jiang ML; Hu F; Li F; Wang K; Tang N; Tang XP; Huang A
iScience; 2022 Nov; 25(11):105465. PubMed ID: 36338432
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
Front Immunol; 2022; 13():908478. PubMed ID: 35844601
[TBL] [Abstract][Full Text] [Related]
17. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
18. Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants.
Hu Q; Zhao Y; Shaabani N; Lyu X; Powers C; Sun H; Cruz V; Stegman K; Xu J; Fossier A; Huang Y; Ho G; Kao Y; Wang Z; Wang Z; Hu Y; Zheng Y; Kyaw L; Zuluaga C; Wang H; Pei H; Allen R; Xie H; Ji H; Chen R
Mol Ther Nucleic Acids; 2022 Dec; 30():465-476. PubMed ID: 36345542
[TBL] [Abstract][Full Text] [Related]
19. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
[TBL] [Abstract][Full Text] [Related]
20. Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
Wang Y; Zhang X; Ma Y; Wang Y; Zhan W; Zheng Q; Zhang M; Ji P; Liu M; Liu Q; Sun T; Zhu T; Wen Y; Sun L; Zhao J; Wu F; Chen Z; Huang J
Cell Discov; 2022 Oct; 8(1):104. PubMed ID: 36207299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
